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Executive Summary  
In Bangladesh, 24 percent of maternal deaths are due to pre-eclampsia and eclampsia (PE/E)—and 
nearly all of these deaths are preventable. With a mission to focus attention and efforts on PE/E, the 
Ending Eclampsia project scaled up PE/E early detection, prevention, and management in 136 primary 
health care (PHC) facilities in Bangladesh, including 20 referral facilities, for over 24 months to assess 
effectiveness and acceptability of under-utilized strategies and commodities to reduce morbidities and 
mortalities of mothers and their babies. This intervention included training on hypertension during 
pregnancy and PE/E, refresher training after three months, and guaranteeing availability of commodities 
and supplies including magnesium sulphate (MgSO4) for intramuscular injections, urine dipsticks, 
syringes and needles, functioning sphygmomanometer and stethoscope, along with a service delivery 
protocol for PHC providers. This pre-post, cross-sectional research design integrated both qualitative and 
quantitative data collection methods at baseline (2015) and endline (2018).  
This intervention, targeting PHC facilities, has resulted in a number of notable successes. A national 
service delivery protocol for PHC service providers’ administration of MgSO4 with referrals was adopted, 
followed by the incorporation of PE/E instruction in PHC providers’ basic curricula, and its inclusion in the 
government’s operation plan for 2017 through 2022, which includes a MgSO4 procurement plan. There 
is evidence of improved PHC provider knowledge, abilities, and practices for detecting, preventing, and 
managing PE/E, improved facility readiness to provide PE/E services, improved quality of care, and 
increased PE/E detection and administration of MgSO4, all with minimum poor outcomes. 
Assessments of facility readiness show significant improvements from baseline to endline in availability 
and functionality of PE/E commodities and supplies in the intervention facilities, particularly blood 
pressure (BP) machines, stethoscopes, urine dipsticks, MgSO4, as well as the service delivery protocol 
for diagnosis and management of PE, severe PE, and eclampsia (PE/SPE/E). Correct knowledge on 
hypertensive disorders, particularly during pregnancy, including PE/SPE/E, significantly improved at 
endline compared to baseline. Similarly, service providers’ diagnostic abilities for SPE/E significantly 
improved at endline—except for chronic hypertension. There was also fourteen-fold increase in knowledge 
of the loading dose of MgSO4 from baseline. All of these findings indicate positive impacts on provider 
knowledge, competence, and facility readiness. 
Provider practice of PE/E detection and management significantly improved at endline. Similarly, provider 
administration of a loading dose of MgSO4 significantly increased from baseline (12%) to endline (48%). 
The quality of antenatal care (ANC) significantly improved as well. No maternal deaths were recorded 
among those who received a MgSO4 loading dose during PHC. These findings are extraordinarily positive 
changes, particularly because PHC facilities had no procedures for PE/E detection, prevention, or 
management prior to the intervention.  
A few areas could benefit from more attention. At endline some patients, albeit a small proportion, with 
severe PE/E (SPE) were not given MgSO4 or refused it. Additionally, the detection rate of hypertensive 
disease in pregnancy (HDP) was still low at endline, which indicates more efforts needed to motivate 
service providers for consistent, correct BP measurement and urine testing for albumin during ANC visits.  
Finally, significant improvement in screening pregnant women for high risk factors during ANC, diagnosis 
of PE/E among ANC and postnatal care (PNC) patients, uptake of PE/E services over 24 months, and use 
of MgSO4 in case of SPE/E at endline are considered as contributions of our implementation of PHC PE/E 
model. Policymakers and program managers, service providers, and other stakeholders strongly advocate 





Globally, approximately 830 women die every day from preventable complications related to pregnancy or 
childbirth, and 7,300 women experience a stillbirth (World Health Organization 2018; WHO, UNICEF, 
UNFPA, World Bank, United Nations Population Division 2015; Lancet 2016). Around 10 percent of women 
experience hypertensive disease of pregnancy (HDP) (Duley et al 2009, Steegers et al 2010). Among them, 
four to five percent present as pre-eclampsia (PE) (Steegers et al 2010, Abalos et al 2013, Arulkumaran et 
al 2013), defined as hypertension with proteinuria after 20 weeks gestation. In low- and middle income 
countries (LMIC), a woman is seven times more likely to develop PE than a woman in a high income country; 
between 10 and 25 percent of these cases will result in maternal death (WHO 2007). 
Although the rates of stillbirths have fallen since year 2000, approximately 2.6 million babies globally were 
stillborn in 2015, or around 7,400 every day. Nearly half were intrapartum stillbirths that are preventable 
with high quality care at birth and early identification of at-risk pregnancies (Lancet 2016). In Bangladesh, 
the risk of dying in the first month of life (neonatal mortality) is 30 per 1,000 live births, accounting for 67 
percent of all under-five deaths (BDHS 2018).  
The Bangladesh Maternal Mortality Survey (BMMS) 2017 revealed that the maternal mortality ratio (MMR) 
remained unchanged, at 196 per 100,000 live births since 2010. Eclampsia remains the second leading 
direct cause of maternal deaths, having increased from 20 percent to 24 percent, after postpartum 
hemorrhage (PPH) (31%): These two causes are responsible for more than half of maternal deaths (54%) 
(NIPORT 2017) in Bangladesh. Among the 5,000 to 6,000 maternal deaths each year in the country, 1,000 
to 1,200 mothers die from eclampsia. Risk of maternal death is high among first-time mothers (215 per 
100,000 live births) as well as those with parities of four or higher. The pregnancy-related mortality ratio 
(PRMR) among the youngest women (15 to 19 years) is 144 deaths per 100,000 live births, compared to 
2,031 per 100,000 live births among women ages 45 to 49 (NIPORT 20117). 
In resource-poor countries such as in Bangladesh, proven life-saving commodities for pregnant women 
have not been optimally examined, such as magnesium sulphate (MgSO4) to manage SPE/E, use of anti-
hypertensives to manage high blood pressure (BP) during pregnancy, aspirin prophylaxis for pregnant 
women at high risk of PE/E, as well as task shifting to lower health worker cadres, and community 
involvement. Hodgins et al. conclude that simple interventions during pregnancy, such as PE/E detection, 
have considerable potential impacts on important mortality outcomes; they found that reliable PE detection 
followed by timely delivery could prevent up to one fourth of newborn and stillbirth deaths, and over 90 
percent of maternal PE/E deaths (2018). There has been no systematic review of research and 
programming on PE/E prevention, early detection, and treatment in Bangladesh. Until recently, PE/E 
policies, health structures, and community perceptions were largely unknown to program implementers or 
service providers.  
With support from USAID, the Ending Eclampsia project has been expanding access to proven, under-
utilized interventions and commodities for PE/E prevention, early detection, and management, particularly 
expansion of MgSO4 access in several countries through primary health care (PHC) providers and 
strengthening global collaboration and partnerships. In 2015, a landscaping analysis including a systematic 
literature review (available at endingeclampsia.org) identified articles reporting PE/E burdens, common risk 
factors, incidence, adverse outcomes, and mortality rates; few studies, however, discuss implementation 
research (IR) for improving PE/E prevention, detection, and timely management, particularly within PHC 
facilities (Warren at al 2016). Following a two year intervention expanding MgSO4 provision through PHC 
providers in 12 sub-districts of Bangladesh, and subsequent data collection, the following report describes 





This pre-post, cross-sectional study, with both qualitative and quantitative data collection methods at 
baseline (2015) and endline (2018), collected data at various levels of PHC in Bangladesh—at Union Health 
and Family Planning Centres (UH&FWCs), referral facilities or where comprehensive emergency obstetric 
and newborn care (CEmONC) is available including Upazila Health Complexes (UHCs), District Hospitals 
(DHs), Mother and Child Welfare Centers (MCWCs), and ANC units of two medical college and hospitals 
(Tangail and Rangpur). The total number of facilities included in the study is 136—at 116 UH&FWCs, 11 
UHs, five MCWCs, two DHs, and two medical college and hospitals. 
Respondents were selected from 12 sub-districts in four districts selected for intervention scale up and IR 
studies. Almost all facilities were the same in pre- and post-data collection, except two that were added in 
post-intervention data collection. The primary sampling unit was a health care facility, with data collected 
at endline from posted, trained, re-trained, and mentored service providers. It is possible, at endline, that 
some service providers, program managers, and policymakers were not the same as those initially 
surveyed, at baseline, due to transfers or new postings. Newly posted providers were duly trained on the 
intervention. A separate sample of client-provider interactions (CPIs), ANC exit client interviews, and PE/E 
survivors were chosen for pre- and post-landscaping analysis. Service use was recorded from all 136 
facilities for 24 months and three months before the intervention. 
Policy and program data were collected at national, district, and lower levels, in interviews with 
policymakers, program managers of maternal and newborn health (MNH) programs, and representatives 
of related local and international NGOs and development partners, to assess policy, programming, and 
informed opinions of them. Facility assessments, interviews with service providers who work in ANC, 
maternity, or labor and delivery wards, client observations of ANC CPIs, and exit interviews with pregnant 
women all aided assessment of facility readiness and service provider knowledge and practice for PE/E 
detection and management, and their quality of care. All PE/E survivors were followed up, monitored, and 
interviewed to assess their care experiences at these facilities, along with the outcomes of their 
pregnancies. Monitoring service use and other related project indicators were collected monthly, over 24 
months, to determine changes in service uptake and project management indicators.  
One IR study (detailed in a separate report) assessed capacity of PHC providers (in a sub-set of facilities) 
to prescribe an oral anti-hypertensive drug to pregnant women and refer them for follow up care. Another 
study followed a cohort of women and their babies who experienced PE/E, to assess postnatal quality of 
care and health outcomes (detailed in a separate report).  
TABLE 1 Data collection for landscaping analysis, by district, n 
Data types 
Comilla Rangpur Tangail Bhola Total 
BL EL BL EL BL EL BL EL BL EL 
Facility inventory 41 41 32 34 31 30 30 31 134 136 
Service provider interview 92 88 68 80 80 89 49 71 289 328 
Client provider interaction 82 10
 
63 84 63 89 60 80 268 353 

















IDIs—eclampsia survivors - 58 - 49 - 57 - 43 22* 50 
IDIs—policymakers, program managers 10 8 9 8 9 7 6 5 50** 36*** 
Monitoring data Monthly service uptake data from 136 facilities, for 24 months 
BL=Baseline, EL=Endline; IDI= in-depth interview  





This post-intervention assessment sought to compare any changes in policy, the health system, and 
community facilities following a two year intervention. Endline data collection had several objectives: 
• Identifying the views and opinions of policymakers, program managers, and other stakeholders of 
PE/E detection, prevention, and management, and a loading MgSO4 dose, during the course of the 
intervention period in Bangladesh; 
• Identifying health system improvements, as well as impediments within the health system, in selected 
facilities for PE/E detection, prevention, and management; 
• Assessing service providers’ knowledge and practices, changes in their quality of care, and knowledge 
of ANC clients attending intervention facilities;  
• Assessing the views and experiences of PE/E survivors administered MgSO4 injections at their 
community (i.e. PHC) facilities; and 
• Investigating uptake of services and changes in project indicators.   
Intervention 
In expanding services to prevent, detect, and manage PE/E, the core intervention in Bangladesh included 
training for PHC providers—Family Welfare Visitors (FWVs) and Sub-Assistant Community Medical Officers 
(SACMOs)—along with nurses or midwives in ANC units, in addition to ongoing mentorship for identifying 
PE/E signs and symptoms, administering a modified loading dose of MgSO4 where needed, and referring 






The PHC PE/E Model was implemented at policy, health system (referral and PHC), and community levels. 
An enabling policy environment was facilitated by the Project Advisory Committee (PAC) formed in 
cooperation with the Director of MCH Services and Line Director (MCRAH) of the Directorate General of FP 
(DGFP), which advised and guided implementation, and collaborated on a PE/E service delivery protocol 
for PHC providers (including the MgSO4 loading dose), complemented by a job aid or algorithm for diagnosis 
and management of hypertension and PE/E and a pamphlet for clients. The project focused on 
institutionalizing PE/E within PHC providers’ basic training curricula, as well as its incorporation in DGFP’s 
operation plan. All service providers at intervention facilities were trained and re-trained on hypertension, 
PE/E, dipstick tests, BP measurement, referrals, and MgSO4 administration. In addition, equipment (e.g. 
BP machines, stethoscopes, dipsticks for urine albumin test, patella hammers, etc.) and commodities (for 
MgSO4 injection) were made available where needed. Field workers were trained on PE/E and pamphlet 
distribution. Community activities were limited to PHC provider and field worker distribution of client 
pamphlets, within facilities and communities, respectively.  
Training covered PE/E’s theoretical and practical elements, including BP measurement, urine analysis (with 
dipstick), MgSO4 injection, risk factors of pregnant women, client follow up, recording, and referral. Service 
providers were first trained for two days, with a one day refresher after three months. Referral facility 
providers were trained on PE/E, mentorship, and patient management after a loading dose of MgSO4.  
The intervention was implemented for 24 months. A total of 51 doctors were trained for their subsequent 
training of 399 PHC providers (FWVs, SACMOs and nurses) and 591 field workers from 12 sub-districts of 
four districts. Although SACMOs do not see ANC patients, they were trained to support FWVs. In addition, 
94 program managers from the four districts were trained prior to the intervention, and 52 during refresher 
training. A refresher training with 217 PHC providers three months after the initial training allowed them to 
share their experiences and resolve any emerging issues.  
A district monitoring officer visited each facility every month. Central Directorate staff provided mentoring, 
in addition to the local program manager, every quarter. The intervention included educational efforts only 
at facilities, with service providers and field workers distributing a PE/E brochure to clients. No intervention 
was implemented within the communities. 
Ethical Review and Informed Consent Process 
The study protocol was reviewed and approved by Population Council’s Institutional Review Board (IRB) in 
New York. The protocol, informed consent forms, and tools were also reviewed by Bangladesh Medical 
Research Council (BMRC)’s Ethics Committee. Participation in the study was voluntary, and informed 
consent was received from all participants before interviews.   
Data Collection and Analysis 
Prior to study implementation, approval and administrative orders were received from both DGFP and the 
Directorate General of Health Services (DGHS). A 33-member data collection team, including six 
supervisors, were recruited and trained for 10 days, on the study’s objectives, its tools, procedures, and 
ethical conduct of data collection. All researchers were trained on data collection in the field for one, outside 
the study area. Four groups, each with five data collectors and one supervisor, were assembled for 
quantitative data collection, with two groups, each with four interviewers and one supervisor, were 




All service providers who participated in the training were selected for an interview. Some service providers, 
program managers, or policymakers interviewed initially may not have been interviewed at endline due to 
transfers or new postings. A separate sample of CPIs, ANC exit client interviews, and PE/E survivors were 
chosen for pre- and post-landscaping analysis. Facility assessments were at the same facilities pre- and 
post-intervention. Monitoring of service uptake and other related project indicators was monthly, for 24 
months, to accurately determine any changes.  
Completed questionnaires were checked by supervisors in the field and sent to the Council’s office for 
editing, entry, and analysis. Quantitative data were edited, coded, entered, and analyzed using STATA/SAS 
software. Data entry utilized CSPro, with double entries to minimize errors. Descriptive, bivariate, and 
comparative analyses (chi-Square test, Fisher’s Exact test, Wilcoxon Rank-Sum Statistic) were performed, 
with results are presented in this report as frequencies and percentages. In few cases, aggregated scores 
were generated in STATA to measure multi-element constructs such as “Assessing Risk of PE/E”. Twenty-
four months of service statistics described service uptake and other project-related indicators (particularly 
PMP indicators). Qualitative interviews were recorded through written notes and audio recordings, then 
transcribed and translated into English. As with baseline data, thematic coding of endline data and allowed 
for comparisons over time. Content and thematic analysis used NVivo software, applying a grounded theory 
approach at baseline and endline, and findings were triangulated by thematic areas. 
This report presents its findings within three broad, inter-related domains: Policy, Health System, and 
Community (Figure 1). The policy domain includes policy on PE/E detection, prevention, and management, 
MgSO4 administration by PHC providers, and stakeholder views and support for task sharing. The health 
system comprises service provider knowledge and practices of PE/E management, HDP, skills in BP 
measurement and urine analysis for albumin, logistics and commodity availability for PE/E management, 
service uptake, program impact, and service quality. Community perspectives include ANC clients’ 
perceptions and understanding of PE/E and pregnancy danger signs, experiences at facilities, and PE/E 




•Policy environment for PE/E detection, prevention, and management 
and administration of MgSO4 by PHC providers, 
and stakeholder views and support for task sharing
Health 
System
•Provider knowledge and practice of PE/E detection, prevention 
and mangement, as well as understanding and definition of HDP
•Provider skills for measuring BP, testing urine albumin, and administering 
MgSO4
•Facility readiness of PE/E commodities and supplies, and HDP 
management
•Quality and uptake of services
Community
•ANC client perceptions and understanding of PE/E, and their experiences 
at facilities
•PE/E survivor experiences of health system care





Selection of Implementation Sites 
Before the study commenced in 2015, a Memorandum of Understanding (MoU) was signed with the 
Directorate General of Family Planning (DGFP), Obstetrical and Gynecological Society of Bangladesh (OGSB) 
and Population Council to work together and a Project Advisory Committee (PAC) was formed to review and 
advise on the project progress. Ending Eclampsia implementation districts have been selected by the DGFP 
considering Country’s geographical and divisional (administrative) distribution. Bangladesh is a 
homogenous country in terms of language, education, and health facility. The functional administrative 
structure is identical from divisional level to union level including health and family planning (FP) services. 
One district, Bhola, is situated in the south, while another, Rangpur, is in the north. The remaining two 
districts, Tangail and Comilla, are in the central part of the country. All of the districts are in different 
administrative areas. Three sub-districts from each district were selected for the intervention, and the 
baseline and endline surveys.  































































Districts & Upazilas: 
Rangpur:  Kaunia, Gangachara & Pirganj  
Tangail:    Kalihati, Madhupur & Bashail 
Comilla:    Daudkandi, Burichong & Debidwar 





Service Providers’ Background Characteristics 
The service providers who participated in the study were primarily women, with a greater proportion at 
endline (p<0.001). Approximately two thirds were 40 years of age or older. At baseline most providers were 
FWVs and SACMOS, while at endline the majority were FWVs and nurses. More referral facility providers, 
compared to PHC providers, were represented at endline. (p<0.001). At baseline, half of service providers 
had received training on FP or maternal, newborn and child health (MNCH) within the past three years, 
compared to all service providers at endline having such training (p<0.001). 
TABLE 2   Service providers’ background characteristics  
Background Characteristics 
Baseline (n=289) Endline (n=328) p- valuea 
n % n %  
Sex 
Male 107 37.0 63 19.0 
<0.001 
Female 182 63.0 265 81.0 
Age (years) 
<30 44 15.0 42 13.0 
0.20 
30-39 42 15.0 68 21.0 
40-49 104 36.0 105 32.0 
>49 99 34.0 113 34.0 
Type of facility 
PHC 187 65.0 143 44.0 
<0.001 
Referral 102 35.0 185 56.0 
Duration of work in ward  
or unit (year) 
<1 9 3.0 16 5.0 
<0.001 
1-5 73 25.0 113 34.0 
6-10 16 6.0 75 23.0 
>10 191 66.0 124 38.0 
Type of provider 
MO Clinic/MOMCH/ 
MO/Ob/Gyn specialist 72 25.0 22 7.0 
<0.001 Nurse 14 5.0 111 34.0 
SACMO 75 26.0 79 24.0 
FWV 128 44.0 116 35.0 
Training in FP, MNCH  
in last three years 
Yes 144 49.8 328 100.0 
<0.001b 
No 145 50.2 0 0.0 
Type of training received** 
EmOC 33 11.0 85 26.0 <0.001 
ANC 38 13.0 80 24.0 <0.001 
Safe delivery care 35 12.0 48 15.0 0.36 
PNC 36 13.0 71 22.0 0.003 
Skilled Birth Attendant training 12 4.0 21 6.0 0.22 
Family planning 60 21.0 90 27.0 0.05 
Laboratory investigations 1 0.4 8 2.0 0.04b 
Emergency newborn/child health - - 146 45.0 - 
PE/E - - 328 100 - 
**multiple responses; a Pearson chi-square test, unless otherwise indicated; b Fisher’s exact test; Significant results are in bold, - not 




Antenatal Care Clients’ Background Characteristics 
A separate sample of clients exiting facilities immediately after ANC were surveyed at baseline (n=768) and 
endline (n=888). All women interviewed were married. In both baseline and endline surveys, about one 
quarter of women were younger than 20 years old, while slightly more than half were 20 to 29 years of age, 
and the rest were 30 years old or older. More than half of the women had a secondary education, at both 
baseline and endline, and a majority were Muslim. Most pregnant women interviewed were of more than 
20 weeks gestation. Most women were attending at least a second ANC visit. Significant differences were 
observed for all background characteristics between baseline and endline among women who were 
interviewed. 







n % n %  
Age (years) 
<20 157 20.0 221 25.0 
0.01 
20-24 274 36.0 277 31.0 
25-29 227 30.0 231 26.0 
>29 110 14.0 159 18.0 
Education 
Never attended school 47 6.0 33 4.0 
0.004 
Primary 237 31.0 231 26.0 
Secondary 395 51.0 488 55.0 
Higher secondary and above 89 12.0 136 15.0 
Religion 
Islam 720 94.0 851 96.0 
0.06 
Hinduism 48 6.0 37 4.0 
Gestational age at interview (week) 
<13 52 7.0 83 9.0 
0.02 
13-20 240 31.0 229 26.0 
21-28 281 37.0 319 36.0 
>28 195 25.0 257 29.0 
Location of ANC facility 
Referral 118 15.0 187 21.0 
0.003 
Primary 650 85.0 701 79.0 
Number of current ANC visit 
1 282 37.0 257 29.0 
<0.001 
2 236 31.0 259 29.0 
3 147 19.0 172 19.0 
>=4  103 13.0 200 23.0 
Socio-economic status 
Lower tercile 318 41.0 276 31.0 
<0.001 Middle tercile 281 37.0 254 29.0 
Upper tercile 169 22.0 358 40.0 





Policy and Programming for Pre-Eclampsia and Eclampsia  
Researchers conducted in-depth interviews (IDIs) with policy stakeholders—including policymakers, 
program managers from the four districts, and development partners, professionals and implementers, as 
well as other stakeholders—at baseline (n=50) and endline (n=37), to identify the policy environment and 
explore stakeholders’ perspectives of relevant issues during the implementation period. 
Pre-Eclampsia Policy  
The government’s PE/E policy falls under 
the broader public health domain of 
maternal health.   The government’s 
standard operating procedure (SOP) 
specifies PE/E prevention and 
management at secondary and tertiary health system levels. The government has yet to formalize any policy 
for PE/E prevention and management at primary (PHC) and community levels of care.  
A service delivery protocol, the Service Delivery Protocol for PE/E for PHC Providers, was developed, tested, 
and approved by the DGFP for implementation in Ending Eclampsia and MaMoni project districts.   
Varied perceptions and confusion were observed 
among informants when discussing the existence 
of a national PE/E policy. While most central 
policy and program managers, as well as other 
stakeholders (i.e. NGOs, development partners), 
are aware of the Service Delivery Protocol for 
PE/E for PHC Providers, many were unsure if 
could be labeled a “policy” document. District 
and sub-district program managers said the government has a policy for reducing maternal and neonatal 
mortality, along with various initiatives such as promoting institutional delivery, 24/7 normal delivery at 
UHFWCs, demand-side financing of maternal and neonatal health in selected sub-districts, the Maternal 
Health Voucher Scheme (DSF-MHVS), and misoprostol distribution through field workers, among others. 
The Ending Eclampsia project endeavored, with PAC guidance, to expand PE/E services to PHC facilities, 
and developed and distributed the Service Delivery Guidelines on PE/E for PHC Providers to all service 
providers and program managers in the project’s four districts and 12 sub-districts.  
“I don’t know about the government policy. There might be one. I can’t tell you about the policy, as 
I didn’t get it yet. I didn’t get the policy in my hand so that I don’t know about where the policy is 
being implemented. There is no implementation policy in my district or upazilas.”  
National program manager and policymaker, MoHFW, Baseline, 2015 
“Definitely there is government policy regarding pre-eclampsia and eclampsia, particularly for the 
secondary and tertiary level facilities. That is national SOP [for maternal health issue], which was 
already developed in 2014 and endorsed. However, government does not have any policy for the 
community level. I have heard that a protocol has been developed and tested in some areas.”  
WHO representative, Baseline, 2015 
“As far as I know, the policy is being implemented all over Bangladesh, otherwise reaching the 
targets of MDGs 4 and 5 were not possible. Of course, we are involved in it, we are providing health 
care services to all types of patients from national, district, and sub-district health facilities.” 
National program manager and policymaker, MoHFW, Baseline, 2015  
PE/E polices are within the larger 
maternal health domain 
A national protocol and service 
delivery guideline for PE/E 





At endline in 2018, awareness had changed.  
“Yes, of course Government has a policy on this matter, and you all are also working as part of this 
policy that loading dose of magnesium sulphate is to be administered to patients with severe pre-
eclampsia and eclampsia. The policy is to prevent death of both mother and child due to pre-
eclampsia and eclampsia. It said, providers who are working at primary health care facility 
especially at grassroot level including FWV in FWC, senior staff nurse or nurse in the antenatal unit 
of UHC and DH are assigned to administer loading dose of magnesium sulphate.” 
District program manager and policymaker, DGHS, Endline, 2018 
“We don’t have any policy regarding PE/E management. We have a guideline regarding this. We’ve 
supplied this guideline to upazila health complexes and they’re working according to that. Doctors 
and Nurses have been trained and now midwifes have joined with them. Midwifes and nurses are 
trained to administer a loading dose of magnesium sulphate and refer. Some works are going on 
accordingly in some places and we’d try to do this in all places.”   
National deputy program manager, DGHS, Endline, 2018 
“I am not aware of any government official policy though I know about the current program being 
conducted by the Population Council.”                          Sub-district program manager, Endline, 2018 
“If we speak officially, there’s no such policy. Population Council has worked in some areas, 
MaMoni has worked in some areas. So, in light of that we’ve made a service delivery guideline for 
fieldworkers with the involvement of DGFP, OGSB and other stakeholders. So, we’re calling this a 
policy. But there’s no exact policy. But this policy can be further implemented with the involvement 
of all stakeholders. We are implementing this in our project areas.” 
NGO stakeholder and implementer, Endline, 2018  
Early Diagnosis and Impacts on Maternal Health 
At baseline, most national policymakers, district program managers, and other stakeholders (i.e. NGOs, 
professional bodies and development partners) stated that early marriage, insufficient ANC service use, 
poverty, and ignorance contribute to the high levels of PE/E in Bangladesh. At both baseline and endline, 
many district managers said PE identification is delayed because women do not seek ANC, resulting in 
negative pregnancy outcomes including maternal and neonatal deaths. Similar statements were made by 
many sub-district managers at baseline, who opined that lack of ANC and general lack of awareness are 
the main reasons for maternal and neonatal 
morbidities and deaths due to PE/E. More than 
three fourths of informants at baseline 
mentioned that PE/E contributed to premature 
delivery, miscarriage, stillbirth, liver damage, 
and death.  
“Due to family barrier [in-laws do not allow], pregnant women do not take antenatal care services 
properly and do not visit us. They usually come at the last moment, when the disease becomes 
severe. They [pregnant women and their families] do not have any knowledge about pre-eclampsia 
and eclampsia. They think it as a simple matter.”     Sub-district program manager, Baseline, 2015 
Similar findings were manifested at endline.  
“The detection of pre-eclampsia is delayed because of the lack of early and regular antenatal care 
check ups. If we can maintain regular antenatal care check ups, bring them to the facility, then 
identification would be early, and the management would be better and easier, and maternal 
deaths would have been greatly reduced, as it contributes 20 percent of maternal deaths.”       
National program manager, DGFP, MoHFW, Endline, 2018  
Lack of ANC and ignorance  
are the main reasons for bad 




“We’re not managing the antenatal care as it should be. We do not bring all pregnant women for 
antenatal care check ups. If we could do that, we could have controlled the blood pressure and 
prevent eclampsia to some extent. Even four antenatal care check ups are not being implemented 
properly. Both the service providers and the patients are responsible for this. The service providers 
don’t serve full time. We’re trying to manage that. Women also have lack of sensitivity and 
awareness. Even if they feel dizzy, they remain at home. They eat one Paracetamol and stay at 
home. However, we are trying to improve this situation to avert pregnancy-related complications.” 
                      National policymaker, DGFP, Endline, 2018 
The need for a protocol and service delivery guidelines for PHC providers was emphasized at baseline, and 
a draft national protocol for PHC providers was reviewed and revised with an expert committee formed by 
DGFP. The resulting Service Delivery Protocol and Guidelines for PHC Providers was distributed widely to 
districts, sub-districts, and PHC facilities. All informants acknowledged receiving the service delivery 
guidelines, and understood the contents and their relevance.  
“I have read the service delivery guideline. As far as I believe, this guideline has no gap. It would 
be helpful for the primary health care providers to understand how to identify pre-eclampsia and 
eclampsia patients, how to manage it, and how to refer. We should use and promote this guideline 
nationwide.”                                                                 District program manager, DGFP, Endline, 2018 
Impact of the Intervention and Task Sharing  
While most informants at baseline supported task sharing with PHC providers (FWVs and SACMOs) to 
detect, prevent, and manage PE/E, some informants had reservations about Community Skilled Birth 
Attendants1 (CSBAs) along with Community Health Care Providers (CHCPs), a clinic cadre who administer 
the MgSO4 loading dose.  
“We need to think whether permission should be given to primary health care providers for… 
injection. Primary health care providers can detect pre-eclampsia and eclampsia by measuring 
blood pressure and urine test. That is simple. After that, they can refer the patients to higher 
facility. But allowing that level of service providers to administer the injection—we definitely need 
to think about it, because we have seen abuse. We do not have any mechanism to stop the 
abuse…doing this, are we causing harm?”                                    Researcher, icddr,b, Baseline, 2015 
For the last two years, progress in all 12 sub-
districts’ PHC systems, and secondary facilities, 
enabled PHC provider PE/E detection and 
management. Policymakers and program 
managers are pleased with the intervention. At 
endline, most informants were satisfied with PHC 
providers’ skills in handling ANC clients with HDP. 
In addition, most informants at endline said this intervention would have great impact in reducing maternal 
deaths if it can be scaled up in other parts of the country. 
“I am managing the PE/E program, we have arranged for a separate room called ‘ANC Corner’. 
There are two SACMOs and a nurse here to provide service…to check the pregnant mother’s 
history, check up, measuring blood pressure, urine albumin test, and manage PE/E patients… 
monitored by me. Population Council’s representatives always is there to help us. I am happy to 
see that our providers are now taking feedbacks from clients and follow up with PE/E survivors.’’  
      Sub-district program manager, DGHS, Endline, 2018 
                                                          
 
 
1  This intervention does not include CSBAs and therefore these concerns are not related to this study or intervention.  
This intervention would have 
great impact if scaled up  




“I was there at the training program as well. I have ensured the availability of MgSO4, anti-
hypertensives, blood pressure machine, logistics at the emergency departments, ANC, PNC 
corners and at the labor room. I’ve checked eclampsia patients personally. I’ve also been at the 
field level and I would like to say that magnesium sulphate is a safe drug, which can be 
administered from any level of health care facility” 
“Training that was arranged by the 
Population Council—for FWV, FWA, SACMO, 
Nurse, Medical Officer, Consultant—had a 
wonderful presentation regarding to whom, 
when and how loading dose of magnesium 
sulphate would be administered. In my 
facility, service providers are now identifying 
PE/E patients, administering loading dose 
and then, referring them to higher level 
facilities.” 
Sub-district program manager, DGHS, 2018 
Scaling up of Interventions 
While informants at baseline had diverse views about whether PHC providers could or should administer 
the modified MgSO4 loading dose, most informants at endline agreed it was necessary to scale up this 
intervention in other parts of the country because of the effects of maternal and neonatal deaths due to 
PE/E. At endline policymakers and program managers said it is essential to implement multiple programs 
that can address maternal and neonatal deaths, in order to achieve SDGs.  
“We say that we made progress in Millennium Development Goals, but still 50 percent of deliveries 
are…at home, and if there is any problem, they first come to the grass root level health workers 
such as the Family Welfare Visitor, CSBA, and SACMO. Women usually go to UH&FWC or Upazila 
Health Complexes or District Hospitals. If we can make the service providers more aware and train 
them at the community level, then they can identify pre-eclampsia and eclampsia, administer the 
loading dose of magnesium sulphate, and refer. Then it will definitely have a good effect and will 
reduce maternal mortality.”                          Representative of development partner, Baseline, 2015 
Progress has been made in scaling up PE/E interventions. DGFP incorporated PE/E within its next five year 
operational plan and included a budget for scale up. In addition, DGHS, in collaboration with OGSB, and 
supported by UNFPA, prepared an “Action Plan for PE/E and PPH,” to which other stakeholders contributed, 
including Ending Eclampsia, and is anticipated to be implemented in 26 districts supported by UNFPA.  
“The objective of Ending Eclampsia project in addressing PE/E is undoubtedly promising. We have 
health providers in the primary level facility, clear management protocol and availability of logistics 
and commodities. Now this intervention is implemented for few areas for couples of years and we 
have the learning, we must expand it in larger scale to get the best result in a short period of time 
otherwise we will not be able to achieve SDGs. As an implementer of the MCH program, I must 
appreciate the simple ways Population Council showed to address a challenging issue. Now we 
should not waste any more time and just scale up this intervention in other parts of the country.” 
National policymaker, MCH program, DGFP, Endline, 2018 
“Definitely the program should be scaled up. Eclampsia is still the number two cause of maternal 
death. If we don’t scale up, we can’t prevent eclampsia. Definitely it needs to be scaled up in all 
districts.”                                                                                   Secretary General, OGSB, Endline, 2018 
 
 
“MgSO4 is a safe drug and can 
be administered from any 




“So, I think the government should be 
proactive to expand the program from these 
four districts to all districts. We OGSB and 
other NGOs should also come forward. We 
have to depend on primary health care 
providers, we can’t use doctors, and we 
don’t have that many doctors available for 
primary health care facilities.” 
                                Former President, OGSB 
“We are ready to scale up the program. We want to expand this program in the entire country. As 
Population Council have trained them, they’ve acquired the skill and now they can refer. Even now 
eclampsia is one of two major causes of death in Bangladesh. So, we definitely want to include 
this program all of the health complexes in all the districts in Bangladesh. We also have an ‘action 
plan’ for pre-eclampsia, eclampsia and postpartum hemorrhage.”  
Program manager, DGHS, Endline, 2018 
“Yes, but I think in Bangladesh, we also have to ask whether the doctors can do it? Because, even 
the doctors can’t do it. I mean…it’s easy to give the dose. The first dose is not dangerous, further 
doses might be. But our problems in Bangladesh is bigger in the community. Our district hospitals 
are not yet managing eclampsia with doctors there, although…there’s no problem with it 
happening at the community…where we need to target is higher up. We got the medical college 
hospitals managing it for the most part. They receive the patients and they put them on a 
reasonable regime, but below that, it’s not very functional. So, our target should be at the district 
hospitals and not yet at the community.”      Representative of development partner, Endline, 2018 
Magnesium Sulphate Supply and Procurement 
The Population Council supplied intervention 
facilities with MgSO4 with the support of the 
MacArthur Foundation. DGFP does not supply 
PHC facilities with MgSO4, but DGHS is supplying 
it to UHCs and DHs, along with calcium gluconate 
(the antidote to MgSO4 toxicity), which remains under-utilized due to the lack of trained providers. Referrals 
of patients to higher level facilities is SOP. While Ending Eclampsia ensured supplies during the 
intervention, DGFP program managers are unsure how to proceed when project support concludes.  
The government should take responsibility for ensuring MgSO4 availability at every health care facility. 
According to policymakers, PHCs receive essential medicines and key equipment, including BP machines 
and urine dipsticks for PE/E detection, directly from the government. It is evident DGFP needs to procure 
MgSO4 for their PHC facilities.  
“Magnesium sulphate, calcium gluconate and anti-hypertensive drugs are not supplied to our 
Family Planning department. It may be supplied to the health department. We usually prescribe 
medicines for the pregnant women who come for treatment and have supplied for blood pressure 
machine, stethoscope, and urine dipsticks.”                  Medical Officer, MCH, DGFP, Baseline, 2015 
At endline it was apparent that MGSO4 had still not been procured for PHCs, at least in some places.  
“It’s still not within our purchasing policy: We are getting supply from Population Council.” 
District program manager, DGFP, Endline, 2018 
“We get the supply from Population Council—magnesium sulphate—can’t buy it from Family 
Planning department, and even not supplied through national supply chain. As per my knowledge, 
it is being purchased in the health department.”               District FP manager, DGFP, Endline, 2018 
DGFP needs to procure MgSO4 
for PHC facilities 
Both DGFP and DGHS need 
their providers to be trained  




“Family planning department will purchase magnesium sulphate from now. We have already put 
this drug in our operational plan and budget is there. We will procure magnesium sulphate very 
soon.”                                                                   Policymaker and implementer, DGFP, Endline, 2018 
“Currently, we actually do not have stock of magnesium sulphate, we’re buying it from CMH. We’re 
procuring magnesium sulphate to supply it to every health complex in each district. We have it in 
our budget and it’s in the process. If we get this, then we can supply this in a while.” 
Program manager, DGHS, Endline, 2018 
“Population Council has been working in four districts, and we’ve also been working with them at 
the primary health care level. So, we would like to have a definite plan and estimate from you, the 
needs for the commodities, so that we can expand it to the entire country. As a part of that plan 
we can arrange to procure specialized drugs like magnesium sulphate...” 
                                                                        Program Manager, DGFP, Endline, 2018 
Health System  
This section describes service providers’ knowledge and practices of PE/E management, in addition to 
logistics and commodities availability, service uptake, quality of care, and program impact. Both the 
baseline and endline surveys collected data on availability and functionality of logistics and commodities 
for PE/E services, to assess changes due to the intervention, in addition to knowledge assessments.  
Facility Readiness 
A facility inventory was conducted at 134 and 136 facilities at baseline and endline, respectively. ANC, PNC, 
and delivery registers were available at most facilities at baseline and endline, but there was a significant 
increase in PNC register availability at endline (95% to 100%, p=0.007). Maternity admission registers were 
only available at 33 percent of facilities at baseline, and at 44 percent at endline (n.s.). Overall findings 
show significant improvements in availability and functionality of facility structures, commodities, and 
supplies for MNH services at most facilities. Few facilities, however, had calcium gluconate available at 
baseline or endline (0.7% and 7.0%, respectively, n.s.). 








n % n %  
Availability of MNH registers 
ANC and referral register 134 100.0 136 100.0 0.10b 
Delivery register 126 94.0 119 88.0 0.06 
PNC register 127 95.0 136 100.0 0.007b 
Maternity admission register 44 33.0 60 44.0 0.06 
Availability and functionality of facility structure for MNH services 
Clean water supply for 24 hours 87 65.0 119 88.0 <0.001 
24-hour power supply 62 46.0 101 74.0 <0.001 
Adequate lighting 78 58.0 99 73.0 0.012 
Functional autoclave/sterilization instruments 93 70.0 108 80.0 0.06 
Infection prevention buckets 123 91.0 134 99.0 0.011b 
Availability and functionality of commodities and supplies for MNH services 
Functional stethoscopes 120 89.0 136 100.0 <0.001b 
Functional sphygmomanometers 114 85.0 136 100.0 <0.001b 




Chlorine solution for disinfecting equipment 110 82.0 112 83.0 0.84 
Xylocaine/local anesthetics 34 25.0 75 55.0 <0.001 
Syringes and needles 111 82.0 129 94.0 0.002 
Normal saline (IV) 58 43.0 126 92.0 <0.001 
IV infusion equipment 39 29.0 71 52.0 <0.001 
Saline stand 72 53.0 98 72.0 0.001 
Facility readiness to manage PE/SPE/E at baseline and endline 
Dipstick on the ward/clinic for testing protein in urine 14 11.0 136 100.0 <0.001b 
MgSO4 loading dose to manage SPE/E 4 3.0 136 100.0 <0.001b 
Calcium gluconate for treating MgSO4 toxicity 1 0.7 10 7.0 0.83b 
Protocol/guidelines for PE/SPE/PE diagnosis, management  10 8.0 136 100.0 <0.001b 
a Pearson chi-square test, unless otherwise indicated; b Fisher’s exact test 
 
Provider Knowledge 
Correct provider knowledge is critical for detecting, preventing, and managing HDP. Service providers’ 
knowledge of HDP and PE/SPE/E were assessed in both the baseline (n=289) and endline (n=328) 
surveys.  
Service providers’ knowledge was assessed within two domains: 1) their ability to define HDP, as well as 
PE, SPE, and eclampsia2 (Table 5, following page), and 2) their ability or capacity to diagnose HDP through 
hypothetical situations (see situations A, B, and C3, Table 6, page 17). Both sets of questions were asked 
at baseline and endline. For comparison, service providers were separated into groups of “physicians” and 
“other service providers” (e.g. FWVs, SACMOs and nurses), and by facility type (PHC or secondary). 
Findings indicate significant improvements in provider knowledge, in defining HDP and PE/SPE/E at endline 
(p<0.001 for each, Table 5). Physicians only showed significant knowledge increases in defining SPE, from 
baseline to endline. FWVs, SACMOs, and nurses increased their knowledge of HDP, PE/SPE/E from baseline 
to endline (p<0.001 for each). Knowledge of PE was lowest at endline among the four definitions assessed, 
even though it increased significantly from baseline (42% at baseline vs. 64% at endline, p<0.001).  
Improvements in knowledge occurred among providers at both types of facilities (PHC and referral), as well 
as among those who had worked at a unit under five years along with those who had worked at a unit more 
than five years (Table 5). Providers who reported training in MCH or FP showed significant improvements 
in knowledge from baseline to endline (p<0.001) compared to those who reported no MCH or FP training 
(Table 5, following page). 
                                                          
 
 
2  Hypertension during pregnancy: BP of pregnant women after 20 weeks of pregnancy is 140/90 mmHg or more; Pre-eclampsia: High BP 
(140/90 mmHg or higher) and presence of albumin in urine determined by dipstick test after 20 weeks of pregnancy; Severe pre-
eclampsia: High BP (140/90 mmHg or higher) + albumin in urine + severe headache, and/or blurred vision, and/or pain in upper 
abdomen; or diastolic BP ≥110 mmHg or systolic ≥160mmHg after two measurements+ albumin in urine; Eclampsia: hypertension 
during pregnancy (140/90 mmHg or greater), albumin in urine, and convulsions during pregnancy 
3  Situation A: A pregnant woman was seen in ANC clinic at 12 weeks gestation with BP 160/100mmHg with no proteinuria, what would 
diagnosis be? Situation B: A pregnant woman was seen in ANC clinic at 30 weeks gestation with BP of 180/115mmHg and proteinuria 
of 2++, what would diagnosis be? Situation C: A pregnant woman developed hypertension and significant proteinuria at 30 weeks 





Table 5 Correct provider knowledge on definition of HDPs by provider type, facility type, experience and training  
Provider knowledge  
and background 
characteristics 

















knowledge 231 (79.9) 324 (98.8) <0.001 120 (41.5) 208 (63.4) <0.001 99 (34.3) 231 (70.4) <0.001 238 (82.4) 307 (93.6) <0.001 
By provider type, n (%) 
Physician 62 (86.1) 22 (100.0) 0.11b 30 (41.7) 14 (63.6) 0.071 38 (52.8) 18 (81.8) 0.015 57 (79.2) 20 (90.9) 0.21 
n 72 22  72 22  72 22  72 22  
FWV/SACMO/nurse 169 (77.9) 302 (98.7) <0.001b 90 (41.5) 194 (63.4) <0.001 61 (28.1) 213 (69.6) <0.001 181 (83.4) 287 (94.0) <0.001 
n 217 306  217 306  217 306  217 306  
By facility Type, n (%) 
Referral facility 84.3 (86.0) 184 (99.5) <0.001b 44 (43.1) 120 (64.9) <0.001 52 (50.9) 133 (71.9) <0.001 82 (80.4) 174 (94.0) <0.001 
n 102 185  102 185  102 185  102 185  
Primary facility 145 (77.5) 140 (97.9) <0.001b 76 (40.6) 88 (61.5) <0.001 47 (25.1) 98 (68.5) <0.001 156 (83.4) 133 (93.0) 0.010 
n 187 143  187 143  187 143  187 143  
By years working in present unit/ward, n (%) 
1-5 years 61 (74.4) 127 (98.5) <0.001b 34 (41.5) 83 (64.4) 0.001 33 (40.2) 101 (78.3) <0.001 70 (85.4) 119 (92.3) <0.001 
n 82 129  82 129  82 129  82 129  
>5 years 86 (41.6) 125 (62.8) <0.001 86 (41.6) 125 (62.8) <0.001 66 (31.9) 130 (65.3) <0.001 168 (81.2) 188 (94.5) <0.001 
n 207 199  207 199  207 199  207 199  
Any training on maternal health, FP and/or child health care, n (%) 
Yes 108 (37.3) 324 (98.8) <0.001b 59 (20.4) 208 (63.4) <0.001b 47 (16.3) 231 (70.4) <0.001b 117 (40.5) 307 (93.6) <0.001b 
n 289 328  289 328  289 328  289 328  






From baseline to endline, there were significant increases SPE diagnostic abilities (56% vs. 99%, p<0.001), 
and to a lesser extent, for eclampsia (97% vs. 100%, p=0.002), through hypothetical situations (Table 6). 
There was no significant increase in overall correct diagnosis of chronic HTN in pregnancy among providers, 
in a hypothetical situation, but a greater proportion of physicians as well as FWVs, SACMOs, and nurses 
made correct diagnoses for chronic HTN in pregnancy and SPE at endline compared to baseline. A greater 
proportion of FWVs, SACMOs, and nurses made correct diagnoses for eclampsia at endline compared to 
baseline. All physicians made correct diagnoses for eclampsia at baseline and endline.  
Significantly more providers employed at a facility for more than five years made correct diagnoses for all 
three situations at endline, compared to baseline. There was only a significant change from baseline to 
endline for SPE diagnosis by service providers who had worked at a facility for one to five years, Nearly all 
providers who had been worked at a facility for one to five years could correctly diagnose eclampsia at 
baseline, and all could at endline.  
Table 6: Case studies of provider knowledge and diagnosis capacity of chronic hypertension,  
severe pre-eclampsia and eclampsia, by background characteristics 





Situation A: Pregnant woman 
presents at 12 weeks with BP 
160/100 mmHg with no 
proteinuria  
(Chronic HTN in pregnancy) 
Situation B: Pregnant woman 
presents at ANC at 30 weeks 
with BP 180/115mmHg  
and proteinuria of 2++  
(Severe PE) 
Situation C: Pregnant woman 
developed HTN and significant 
proteins at 30 weeks, brought 
back a week later  
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n 72 22  72 22  72 22  











n 217 306  217 306  217 306  
By facility Type, n (%) 












n 102 185  102 185  102 185  











n 187 143  187 143  187 143  
By years working in present unit/ward, n (%) 
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n 207 199  207 199  207 199  
Any training on maternal health, FP or child health care, n (%) 
Yes 114 (39.5) 
295  
(89.9) <0.001
b 77  (26.6) 
325  
(99.1) <0.001




n 289 328  289 328  289 328  




From baseline to endline there was significant improvement in knowledge among FWVs, SACMOs, and 
nurses of specific BP for initiation of anti-hypertensive drugs for mild to moderate HDP (43% vs. 57%, 
p=0.002, Table 7). This improvement was not seen among physicians. Knowledge of precise BP for 
initiation of anti-hypertensive drugs for severe HDP decreased from eight percent to four percent (p=0.08). 
TABLE 7 Service provider knowledge of blood pressure during pregnancy for initiation  
of anti-hypertensive drugs, at baseline and endline 
Knowledge on when to initiate antihypertensive drug 
for severity of hypertension 
Baseline (n=289) Endline (n=328) p- 
valuea n % n % 
Knew exact BP for initiation of anti-hypertensive 
drugs for mild to moderate HDP 161 56.0 196 60.0 0.37 
Physician 67 93.0 21 95.0 0.69 
n 72 22  
FWV/SACMO/Nurse 94 43.0 175 57.0 0.002 
n 217 306  
Knew exact BP for initiation of anti-hypertensive 
drugs for severe HDP 22 8.0 14 4.0 0.08 
Physician 18 25.0 5 22.0 0.83 
n 72 22  
FWV/SACMO/Nurse 4 2.0 9 3.0 0.10b 
n 217 306  
a Pearson chi-square test, unless otherwise indicated; b Fisher’s exact test 
There was a significant improvement in service providers’ correct knowledge of the total loading dose of 
MgSO4 and its toxicity, from baseline and endline4—a more than fourteen-fold increase (p<0.001, Table 8). 
All service providers knew the correct total loading dose at endline. Provider knowledge of the MgSO4 
maintenance dose for SPE/E improved significantly from baseline to endline, but the proportion at endline 
was lower than expected (5% vs. 22%, p=<0.001).  
Further knowledge of MgSO4 toxicity was also assessed among service providers. Knowledge of at least 
one sign or symptom of MgSO4 toxicity, ways to monitor for it, and antidotes significantly increased from 




                                                          
 
 
4  The two most commonly used regimens for administering MgSO4 to prevent and treat convulsions in the case of severe PE/E are the 
Zuspan regimen (a loading dose of 4 g IV, and maintenance dosing of 1 g/hr IV) and the Pritchard regimen (loading doses of 4 g IV and 
10 g IM, and maintenance dosing of 5 g IM/4hr). The Pritchard regimen is considered the ‘gold standard’ using both an intravenous (IV) 
loading dose including intramuscular (IM) dose and IM maintenance doses.  
A modified loading dose called “Dhaka regimen” (10mg IM loading dose and referral to higher facility for further management) has been 
shown effective in a hospital setting and in primary health care setting (Begum et al 2002 and Shamsuddin et al 2005) and was further 
tested at primary health care level in Bangladesh (OGSB 2014, Save the Children 2015). The “Dhaka regimen” has been approved by 
the National Technical Committee (NTC) of DGFP for introduction in the national health system (NTC 2015) and is the regimen used by 




TABLE 8 Service providers’ correct knowledge on total loading and maintenance doses  
of magnesium sulphate, and its toxicity, at baseline and endline 
Knowledge of loading dose of MgSO4 
Baseline (n=289) Endline (n=328) 
p- valuea 
n % n % 
Knew total loading dose of injection of MgS04  
for SPE/E (Dhaka regime) 21 7.0 328 100.0 <0.001
b 
Physician 18 25.0 22 100.0 <0.001b 
n 72  22   
FWV/SACMO/Nurse 3 1.0 306 100.0  <0.001b 
n 217  306   
Knew maintenance dose of MgS04 for SPE/E 
(Pritchard regime) 14 5.0 72 22.0 <0.001 
Physician 14 20.0 16 73.0 <0.001 
n 72  22   
FWV/SACMO/Nurse 0 0 56 18.0 <0.001b 
n 217  306   
Knew at least one sign or symptom of MgS04 
toxicity 41 14.0 121 37.0 <0.001
 
Physician 37 51.0 21 95.0 <0.001 
n 72  22   
FWV/SACMO/Nurse 4 1.8 100 33.0 <0.001b 
n 217  306   
Knew all ways (depressed respiratory rate, loss  
of tendon reflex, decreased urine output) to monitor 
MgS04 toxicity 
14 5.0 40 12.0 0.001 
Physician 13 18.0 10 46.0 0.021 
n 72  22   
FWV/SACMO/Nurse 1 0.01 30 10.0 <0.001b 
n 217  306   
Knew antidote (calcium gluconate) for MgS04 
toxicity 25 9.0 77 24.0 <0.001
 
Physician 24 33.0 17 77.0 <0.001 
n 72  22   
FWV/SACMO/Nurse 1 0.01 60 19.0 <0.001b 
n 217  306   







Program effectiveness was measured with various indicators including provider experience in administering 
loading dose of MgSO4, improvement of in-service provision and referral mechanisms, PE/E detection and 
prevention practice, ANC client experiences, improved quality of care, and service uptake.  
Administration of loading dose of MgSO4 significantly increased from baseline to endline (12% vs. 48%, 
p<0.001, Table 9). This significant increase occurred for physicians as well as for FWVs, SACMOs and 
nurses. Not all service providers may have had the opportunity to administer a loading dose of MgSO4 due 
to lack of PE/E clients. At baseline, 91 percent of providers reported that clients or their families were 
reluctant or refused to take an injection during pregnancy, compared to 17 percent at endline, and only a 
small number of providers felt confident in administering an MgSO4 injection. At endline, client perceptions 
had changed due to provider counseling, but a provider challenge was their fear of a community’s reaction 
if a woman with PE/E had a negative outcome after receiving MgSO4. 
TABLE 9 Service provider experiences administering magnesium sulphate loading dose  
and operational challenges, at baseline and endline 
Practices on loading dose of MgSO4 
Baseline (n=289) Endline (n=328) 
p- valuea 
n % n % 
Had administered loading dose  35 12.0 157 48.0 <0.001 
Physician 29 40.0 17 77.0 <0.001 
n 72  22   
FWV/SACMO/Nurse 6 2.8 140 46.0 <0.001 
n 217  306   
Confident/skilled in administering loading dose  132 46.0 310 94.0 <0.001 
Physician 58 80.0 22 100.0 0.035b 
n 72  22   
FWV/SACMO/Nurse 74 34.0 288 94.0 <0.001 
n 217  306   
Operational challenges for loading dose  129 44.6 82 25.0 <0.001 
Physician 50 69.4 9 40.9 0.015 
n 72  22   
FWV/SACMO/Nurse 79 36.4 73 23.8 0.002 
n 217  306   
Type of operational challenge for loading dose** 
Reluctance/refusal of patient/family for injection 118 91.0 14 17.0 
<0.001 Provider fear of community reaction to negative 
outcome after MgSO4 use 11 9.0 68 83.0 
n 129  82   
Providers who fear community reaction and felt 
confident/skilled administering loading dose  8 72.3 64 94.1 0.05
  
By Provider type (11)  (68)   
Physician 2 66.7 7 100.0 0.30b 
n 3  7   
FWV/SACMO/Nurse 6 75.0 57 93.4 0.14 
n 8  61   




At endline, service providers were asked to report on their service provision after their PE/E training. (These 
questions were not asked at baseline.) Ninety percent of service providers reported that they were able to 
identify more hypertensive patients after PE/E training, and 96 percent reported that they could identify 
ANC patient risk for PE/E or obstetric complications after the training (Table 10). Forty-eight percent of 
service providers reported subsequent PE/E patient management, with significantly more physicians than 
FWVs, SACMOs, and nurses (77% vs. 46%, p=0.004). Twenty-four percent of patients were managed at 
PHC facilities, compared to 76 percent at referral facilities. Physicians managed PE/E at referral facilities 
only, along with 73 percent of FWVs, SACMOs, and nurses, with 27 percent of FWVs, SACMOs, and nurses 
managing PE/E at PHC facilities (p=0.013).   
TABLE 10 Provider self-reports of service provision following intervention, n (%) 
 
Total (n=328) Physician (n=22) 
FWV/SACMO/
Nurse (n=306) p- value
a 
Identify more hypertensive patients after received PE/E training?   
Yes 296 (90.0) 21 (96.0) 275 (90.0) 0.60b 
Identify ANC patient’s risk for PE/E or obstetric complications?   
Yes 313 (96.0) 21 (95.0) 292 (94.0) 0.10b 
PE/E risk factors examined with ANC patients* 
Age <20 and > 35 years 303 (92.0) 21 (96.0) 282 (92.0) 0.57 
Primigravida 151 (46.0) 13 (59.0) 138 (45.0) 0.20 
Number of pregnancies >=4 times 209 (63.0) 18 (82.0) 191 (61.0) 0.06 
Birth spacing less than 2 years 110 (34.0) 13 (59.0) 97 (32.0) 0.010 
Height 145 cm or less 261 (80.0) 19 (86.0) 242 (79.0) 0.41 
Previous pregnancy history e 164 (50.0) 3 (12.0) 269 (88.0) <0.001b 
Current pregnancy history f 165 (52.0) 2 (10.0) 275 (90.0) <0.001b 
Manage PE/E patient 
Yes 157 (47.9) 17 (77.3) 140 (45.8) 0.004 
Management of PE/E by facility type 
Primary facility  38 (24.0) 0 (0.0) 38 (27.0) 
0.013b 
Referral facility  119 (76.0) 17 (100.0) 102 (73.0) 
n 157 17 140  
*Multiple responses; a Pearson chi-square test, unless otherwise indicated; b Fisher’s exact test;  
e: Hemorrhage at ANC, hemorrhage at PNC, retained placenta, Prolonged labor, HTN/PE/ E in previous pregnancy, Premature baby death, 
caesarean section history; f: High blood pressure, Diabetes, Heart diseases, Jaundice, Twin Pregnancy, Kidney problem 
 
An important process of service provision improvement was to establish a functional referral mechanism 
for PE/E patients—from PHC to referral facilities—and use of a project-developed referral slip. Questions 
about the referral mechanism were only asked at endline. Eighty-one percent of providers thought the 
Ending Eclampsia referral mechanism was effective. Significantly more providers from referral facilities 
(85%) thought the referral mechanism was effective, compared to 76 percent from PHC facilities (p=0.034, 
Table 11).  
Sixty-nine percent of providers used the referral slip to refer patients to a higher facility. Fifty-nine percent 
of providers referred PE/E patients to higher level facilities (n=192), and of those, 89 percent reported that 
those patients went to a referral facility for services (n=170), and of those, 94 percent reported that the 
health care facility solicited their responses or contacted them after their referrals, for the purposes of the 





TABLE 11 Service providers’ views of referral mechanisms for PE/SPE/E at endline, n (%) 
Referral Mechanism Total (n=328) Primary (n=143) Referral (n=185) p- valuea 
Was Ending Eclampsia referral mechanism effective? 
Yes 267 (81.0) 109 (76.0) 158 (85.0) 0.034 
Used referral slip to refer patients to higher facility? 
Yes 226 (69.0) 100 (70.0) 126 (68.0) 
0.72 
No 102 (31.0) 43 (30.0) 59 (32.0) 
Referred PE/E patients to higher facility? 
Yes 192 (59.0) 73 (51.0) 119 (64.0) 
<0.001 No 60 (18.0) 16 (11.0) 44 (24.0) 
Not found any PE/E patients 76 (23.0) 54 (38.0) 22 (12.0) 
n 328 143 185  
Did patients go to higher facility to receive referral services 
Yes 170 (89.0) 68 (93.0) 102 (86.0) 
0.06 
No 22 (11.0) 5 (7.0) 17 (14.0) 
n 192 73 119  
Has facility collect feedback/contact with patients after referred 
Yes 159 (94.0) 68 (100.0) 91 (89.0) 
0.003b 
No 11 (6.0) 0 (0.0) 11 (11.0) 
n 170 68 92  
a Pearson chi-square test, unless otherwise indicated; b Fisher’s exact test 
Provider Practices for Screening and Prevention 
Client-provider interactions (CPIs) were 
observed at all facilities to assess provider 
practices for PE risk assessment, 
screening, and information provided to 
clients. While one CPI was planned for 
each provider, in a few cases multiple CPIs 
of one provider occurred, particularly at 
endline. Box 1 presents the definitions 
used for assessing PE risk, screening for 
PE, and advising on SPE, through 
composite scores for each. Findings from 
observation data show that service 
providers poorly measured all three components (assessing PE risk, screening for PE, and advising on SPE) 
at baseline, but this significantly improved at endline (Table 12). While assessments of PE risk and advice 
on signs and symptoms significantly improved, these practices were still quite low at endline. 
TABLE 12 Provider practices observed during client-provider interactions (for each component) 
 Baseline (n=268) Endline (n=353) p- value 
n % n %  
Assessed risk of PE 29 10.8 96 27.2 <0.001 
Screening for PE 4 1.5 218 61.8 <0.001 
Advise of signs/symptoms of SPE 9 3.4 85 24.0 <0.001 
Box 1: Definitions Used to Assess Pre-Eclampsia Risk,  
Detect Pre-Eclampsia, and Advise of Impending 
Eclampsia During CPI Observations 
 
Assessing Pre-Eclampsia Risk: History of hypertension or 
high blood pressure, client weight, check for edema (face, 
hands, legs, ankles), pregnancy order, and client age 
Detecting Pre-Eclampsia: Client blood pressure  
and urinalysis (protein/albumin) 
Advising of Severe Pre-Eclampsia Symptoms: Severe 
headache, blurred vision, high blood pressure, and 




Five variables (Box 1) measured providers’ practices in assessing PE risk, with a summary score for each 
observation representing the number of variables assessed—0 representing none, 1 representing one risk 
assessed, up to 5 representing all five risks assessed (The numerals 1 to 4 do not indicate any specific 
variables, but a score of 5 necessarily includes all five variables).  
Observations indicate significant improvement, with service providers for assessing four or five risk factors 
at endline, compared to three or four at baseline. Further analyses show that the three most frequently 
assessed factors were birth order (100%), client weight (82%), and edema (72%) at baseline, and birth 
order (100%), client weight (88%), and client age (86%) at endline, while patient history questions on 
hypertension were less frequently checked (16% to 40%, baseline and endline, respectively).  
 
Similar summary scores were generated for each observation of providers screening for PE, which 
comprises two variables: BP checks and test for albumin in urine. Summary scores generated for each 
observation show aggregated number of checks for PE screening—1 representing one check and 2 
representing two checks. Endline data suggest higher proportions of observed BP checks (98%) than 
proteinuria tests (62%). Baseline data suggest a much lower proportion of proteinuria checks (2%) than BP 
checks (81%). 
 
Note: Summary scores generated for each observation shows aggregated number of checks for PE screening (1 representing one check 










































Summary PE Risk Assesment score (1-5)
Figure 1: Number of PE risk factors assessed during CPI observation


































Sumary of PE Screening score (0-2)
Figure 2: Number of PE screening assessed during CPI observation




Similar summary scores were generated for each observation to measure provider practice in advising 
women of PE signs and symptoms, with an aggregated number of signs and symptoms for which advice 
was provided (0 representing none, 1 representing one piece of advice, up to 4 representing advice for all 
four signs and symptoms; 1 to 3 do not indicate any specific variables; for example, 1 can be any variable 
and so on, but 4 will be all four variables). Findings indicate significant improvements for provider advice 
to women of different pregnancy signs and symptoms, particularly two to four signs or symptoms, and a 
decrease in “no advice” at endline. At baseline most providers either advised on one sign or symptom, or 
none, and this significantly improved at endline. Edema was the most frequently advised (84%) sign or 
symptom at endline, followed by severe headache (63%), high BP (53%), and blurred vision (50%), 
compared to edema (71%), severe headache (25%), high BP (12%), and blurred vision (12%) at baseline. 
 
Clients’ Experiences at Facilities and Quality of Care 
To determine pregnant women’s perceptions of their quality of care, as well as their understanding of those 
services, the project conducted client exit interviews after CPI observations were complete. There was 
significant improvement in all nine necessary ANC components except two: abdominal and fetus heartbeat 
examination. Significantly more clients reported receiving all nine ANC components at endline (1% at 
baseline vs. 33% at endline, p<0.001). 
TABLE 13 Services received during ANC visit, at baseline and endline 
ANC service components 
Baseline (n=768) Endline (n=888) 
p- value 
n % n % 
Measured weight 605 79.0 765 86.0 <0.001 
Checked BP 696 91.0 856 96.0 <0.001 
Examined abdomen 616 80.0 733 83.0 0.22 
Checked for anemia 562 73.0 727 82.0 <0.001 
Listened to baby’s heartbeat 403 53.0 479 54.0 0.55 
Checked urine for protein and sugar 34 4.0 578 65.0 <0.001 
Told about the progress of pregnancy 546 71.0 698 79.0 <0.001 
Given chance to ask questions 591 77.0 754 85.0 <0.001 
Told to return for another visit 657 86.0 863 97.0 <0.001 
Told about hypertension during pregnancy - - 412 46.0 - 
Told about PE/E - - 699 79.0 - 
Proportion of clients received all 9 ANC components  8 1.0 292 33.0 <0.001 




































Summary SPE symptom advice score (0-4)
Figure 3: Number of SPE signs/symptom advice assessed during CPI observation




Although waiting times increased, clients reported more time with their providers. Although quite high at 
baseline, significantly more clients reported being satisfied or somewhat satisfied with their services on the 
day of the survey at endline (91% at baseline vs. 99% at endline, p<0.001). Ninety-eight percent of clients 
at endline would recommend a friend attend the same facility for ANC, compared to 89 percent at baseline 
(p<0.001).  
TABLE 14 ANC client experiences at baseline and endline 
Quality of care Issues Categories 
Baseline (n=768) Endline (n=888) 
p- valuea 
n % n % 
Waiting time before being seen 
by service provider (minutes) 
<30 651 85.0 668 75.0 
<0.001 
>30 117 15.0 220 25.0 
Perception about waiting time 
Too long 102 13.0 126 14.0 
0.85 
Reasonable 612 87.0 762 86.0 
Time spent with the service 
provider (minutes) 
<15 664 87.0 524 59.0 
<0.001 
>15 104 13.0 364 41.0 
Perception about time spent  
with the service provider 
Too long 15 2.0 45 5.0 
<0.001 Reasonable 550 72.0 749 84.0 
Too short 203 26.0 94 11.0 
Satisfaction of service received 
that day 
Satisfied,   
somewhat satisfied 696 91.0 872 99.0 <0.001 
Not satisfied at all 72 9.0 16 1.0 
Would recommend a friend  
to come to this facility for ANC Yes 686 89.0 866 98.0 <0.001 
a Pearson chi-square test, unless otherwise indicated; b Fisher’s exact test 
Generally, client knowledge of danger signs during pregnancy was low at baseline, and significantly 
improved at endline (p<0.001, Table 15). Although there were significant improvements, there still appear 
to be gaps in client knowledge, however.  
TABLE 15 ANC client knowledge of danger signs during pregnancy 
Indicator 
Baseline (n=768) Endline (n=888) 
p- valuea 
n % n % 
Awareness of danger signs of pregnancy* 
Severe Headache 174 23.0 502 56.0 <0.001 
High fever 119 16.0 576 65.0 <0.001 
Upper abdominal pain 119 16.0 191 22.0 0.002 
Blurred vision 36 5.0 168 19.0 <0.001 
Excessive bleeding 267 35.0 454 51.0 <0.001 
Convulsion 163 21.0 385 43.0 <0.001 
Obstructive/prolonged labor 81 11.0 247 28.0 <0.001 
Generalized edema 101 13.0 118 13.0 0.934 
Absent of fetal movement 22 3.0 200 23.0 <0.001 
Number of danger signs during pregnancy client knew 
None 134 17.0 13 2.0 
<0.001b 
1 277 36.0 67 7.0 
2-4 357 47.0 646 73.0 
>4 0 0.0 162 18.0 





Service statistics and project indicators were collected from 136 facilities at baseline (for 3 months), and 
then monthly for 24 months. At baseline, an average of 16 PE, seven severe PE (SPE), and 47 eclampsia 
patients were seen per month, and those figures significantly increased, to monthly averages of 28 PE, 19 
SPE, and 65 eclampsia patients during the intervention period (p<0.001, p<0.001, p<0.001, respectively, 
Table 16; appendices A and B show monthly distribution of all 24 months of data and three months of 
baseline).  
Table 16 Uptake of services at baseline and for 24 months of intervention period, with changes 



















 Total Monthly Total Monthly   
Women with PE seen at facility            n  48 16.0 664 27.7 43% <0.001 
Women with SPE seen at facility          n 20 6.7 445 18.5 63% <0.001 
Women with eclampsia seen at facility 142 47.3 1554 64.8 28% <0.001 
Women with SPE/E treated  
with MgSO4                                              n 33 11.0 1,910 79.6 86% <0.001 
 % 20%  96%   - 
ANC visits per month  
(repeat and new visits)                           n 33,754 112,151.3 334,305 13,929.4 19% <0.001 
Women whose BP was measured 
during ANC                                              n 27,404 9,134.7 320,379 13,349.1 32% <0.001 
 %  81%  96%   - 
Women whose urine was checked  
for albumin at ANC visits                       n 1,943 674.7 156,527 6,521.9 90% <0.001 
% 6%  47%   - 
Pregnant women detected as high risk 
during ANC                                              n 2,796 932 77,503 3,229.3 71% <0.001 
% 8%  23%   - 
Pregnant women detected  
with high BP during ANC                        n 167 55.7 3,958 164.9 66% <0.001 
% 0.5%  1.2%   - 
Mid-level providers trained in PE/E 
management, intervention area 
(refresher)*                                             n 
399  217*    
Mid-level providers who can correctly 
identify and detect PE                           % -  93%    
Mid-level providers who can correctly 
identify and detect eclampsia              % -  94%    
Mid-level providers trained to 
competence in appropriate anti-
hypertensive use  
(49 pre-intervention, 44 refresher)      % 
-  100%    
Trained service providers prescribing 
anti-hypertensives to control BP  
for PE/E patients, intervention area 




month    
Pregnant women who attended ANC 
aware of 2+ PE/E signs/symptoms     %  -  34%    




Rates of PE/SPE/E diagnoses increased during the intervention (Figure 4), particularly for eclampsia.  
 
During the baseline period, an average of 11 SPE/E patients each month were given MgSO4 to prevent and 
control seizures (20% of the total seen with SPE/E at the 136 facilities). At endline, there was an eight-fold 
increase in women given MgSO4--80 SPE/E per month over 24 months, 96 percent of the total SPE/E 
women seen at the 136 facilities in that time period, Table 16, Figure 5). This increase in treatment of 
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Figure 4 Rate of PE/SPE/E diagnoses among ANC+PNC clients
Diagnosis rate of PE Diagnosis rate of SPE
Diagnosis rate of eclampsia Total PE/SPE/ E diagnosis rate

















































Figure 5 Administration of MgSO4 loading dose among SPE/E patients






To detect, prevent, and manage PE/E, correct measurement of BP and urine testing for albumin is key. The 
service providers in all intervention facilities were trained for competency in BP measurement, urine testing 
for albumin, and loading dose administration of MgSO4. While 81 percent of ANC patients had their BP 
measured at baseline, and six percent of ANC patients’ urine was checked for albumin, at endline both BP 
measurement and albumin testing had significantly increased, to 96 percent and 47 percent, respectively, 
at endline (p<0.001, Table 16). 
Screening pregnant women during ANC for high risk factors is extremely important for their successful 
detection. At baseline screenings by service providers for risk factors in women resulted in only eight 
percent of pregnant women assessed as high risk, which significantly increased to 23 percent at endline 
(p<0.001). Detection of high BP among pregnant women also significantly increased, from 56 per month 
at baseline to 165 per month—a threefold increase at endline (p<0.001). The proportion of high BP 
detected during ANC among all pregnant women at baseline was 0.5 percent, compared to 1.2 percent at 
endline (p<0.001, Table 16).   
Survivors’ Experiences  
A different sample of PE/E survivors was interviewed in-depth at baseline and endline. At baseline, 22 PE/E 
survivors at a tertiary medical college hospital were interviewed, and at endline 50 survivors from the 
community who were treated at intervention facilities were interviewed. These PE/E survivors were 
interviewed to assess their knowledge, attitudes, views, and experiences of PE/E, ANC experiences of PE/E 
education and screening, the accessibility of essential services and commodities, and their understanding 
of both the means and courses to appropriate health care. 
Antenatal Care  
At baseline, slightly more than two thirds of PE/E survivors had an ANC check up before being admitted to 
a tertiary hospital, but the quality of their ANC was poor, and they were dissatisfied with the services. Many 
respondents believed that a fetal ultrasonogram was the major element of ANC.  
Although BP was measured in most cases at baseline, a urine albumin test was not done three fourths of 
the time. Among PE/E survivors interviewed at baseline, about one fifth had elevated BP at an ANC check 
up and ended up in a tertiary hospital with SPE/E. Almost all of those who attended ANC at baseline 
reported that their service providers gave no information on possible pregnancy issues or danger signs, nor 
no explanation of the significance of high BP during pregnancy.  
“I got pregnant within three months after my marriage, and did the first check up and 
ultrasonogram at eighth month from a private clinic. A female doctor checked me and found low 
blood pressure and suggested for nutritious food, weekly check up, medicine, and assure[d] for 
normal delivery. I had swollen legs from seventh month and headache, but doctor didn’t say 
anything about it. I thought it is normal in pregnancy. Few weeks later, I had delivery pain with 
convulsions at midnight. My family took me to a private clinic, they gave me an injection and 
referred to another hospital and subsequently, they also referred me to Dhaka Medical College 
hospital.”                                                                                                     PE/E survivor, Baseline, 2015 
At endline, most PE/E survivors had visited a government health care facility for normal ANC and had 
received ANC services more than three times, an improvement from baseline. At endline many PE/E 
survivors had not had an ANC check up until a problem arose, however. Many PE/E survivors who 
experienced problems including headache, blurred vision, abdominal pain, edema, fever, and leaking 




was diagnosed in the seventh month of pregnancy, and in few cases, just before delivery. This may be due 
to a delayed ANC check up at a facility or miscalculation of patient gestation.   
“I have taken antenatal care services four times. I was taking my first…when I was third month of 
pregnancy. I was there for a normal check up. In my every check up blood pressure was measured 
and urine tested. During my first visit, my pressure was normal. My pressure was diagnosed at my 
seventh month of pregnancy.”                                                  PE/E survivor, UH&FWC, Endline, 2018 
“I had never visited any health facility during my pregnancy. I was in Pirganj, at my father’s home, 
four kilometers away from Upazila Health Complex hospital, with the hope to deliver there. One 
day, I had severe abdominal pain when I was nine months pregnant. During my pregnancy, I used 
to take sacred water from a traditional healer near my parents’ home. I think my abdominal pain 
was due to the sacred water. I was then taken to the hospital and diagnosed with high blood 
pressure. The Family Welfare Visitor g[ave] me two injections at my buttocks, and then referred me 
to Rangpur Medical College Hospital. When the pain went, and I feel better, I went to my parents’ 
home again. I had a normal delivery at my parents’ home.” 
PE/E survivor, Pirganj UHC, Endline, 2018 
At baseline most PE/E survivors were unaware of their high BP and did not know about the signs or 
symptoms of SPE/E. At endline, most PE/E survivors had also not been fully counseled on danger signs in 
pregnancy. Those who received ANC (about one third of PE/E survivors), said that they knew pregnant 
women can suffer from hypertension.  
“I see a leaflet given by the field workers, but I did not understand what is written there. No one 
make me understand what is written there.”                                   PE/E survivor, UHC, Endline, 2018 
Pregnant Women Seek Care Late 
Community behaviors, particularly for seeking pregnancy care, did not change over time. At baseline, even 
with problems with high BP, women remained at home, in the hope or belief such a problem was not very 
serious, or they visited village doctors, Imams, or traditional or spiritual healers. About half of PE/E survivors 
at endline also did not seek ANC until there was a problem.  
“I have no check up myself, while I was pregnant. I...visited the Pachgachi Union Health and Family 
Welfare Centre at eighth month of my pregnancy, with abdominal pain. The Family Welfare Visitor 
diagnosed me with high blood pressure. She counseled me about the consequences of high blood 
pressure and also told me that convulsion can happen. She referred me to Upazila Health Complex 
for further treatment, but I never went there until I had a convulsion.” 
PE/E survivor, FWC, Endline, 2018 
Magnesium Sulphate Administration 
Information on the timing of MgSO4 administration, survivors’ feelings after the injection, and any PNC 
check ups were collected from PE/E survivors at endline. At baseline, no patient had received MgSO4 at a 
PHC facility, while at endline most PE/E survivors stated they had visited a nearby (i.e. PHC or secondary) 
facility with problems such as headaches, blurred vision, high BP, abdominal pain, or convulsion, and their 
service providers had administered a MgSO4 injection. Some survivors even reported visiting the facility for 
a normal check up when their BP was found to be high, and then providers administered the two injections 
and referred them to another facility. Most PE/E survivors had no problems or side effects after their loading 
dose of MgSO4, although a few experienced pain in the injection area for few days. Most patients presented 
at the referral facility after the loading dose injection from primary or secondary facilities, but a few patients 




“I went to the Family Welfare Centre to know my blood pressure while I was eight months pregnant. 
I heard that pressure may be high or low during pregnancy. The apa [FWV] at the facility told me 
that my blood pressure is too high. She advised me that I need to take two injections now and then, 
consult with another facility or a physician. Then, she administered two injections at my buttocks 
and referred to Burirchong Upazila Health Complex.”            PE/E survivor, UH&FWC, Endline, 2018 
“When I was ninth month[s] pregnant, I went to nearby Family Welfare Centre due to blurring of 
vision, convulsion, and labor pain. She said I have high blood pressure. She suggested me to go 
Upazila Health Complex immediately after having some injection. She administered two injections 
and gave me one tablet. After that I went to Debidwar Upazila Health Complex, where I had a 
normal delivery. I went for postnatal care services regularly, as my pressure was high, and took 
medicines, and now, my pressure is normal.”                         PE/E survivor, UH&FWC, Endline, 2018 
A few PE/E survivors did not present to the referral facility, for various reasons including transportation 
problems, financial issues, or lack of family member for accompaniment.   
“At the last stage of my pregnancy I had convulsions and I was brought to nearby Family Welfare 
Centre. I had delivery pain also. That time, apa administered me two injections [MgSO4] in my two 
buttocks and suggested my family to take me to the district hospital. My family refused to go there 
at that time, because there was no one to accompany me. We said, apa do what you can do, 
Almighty will save me. After some time, a normal baby boy was born, and my seizures become 
reduced. I stayed at the Family Welfare Centre for three hours, and there was no repeated 
convulsion. I have received three postnatal care check ups, the first two in Family Welfare Centre, 
and the third one in Bhola District Hospital. My pressure is normal now.”  






Baseline and intervention data collection were separated by two years, to compare changes in policies, the 
health system, and community perspectives of PE/E after the introduction of a well-defined PHC 
intervention to strengthen their providers’ capacities. This intervention, with FWVs, SACMOs, and nurses in 
136 facilities, also oriented referral facility care providers on referred PE/E patients’ care and management.  
One policy success was the project’s support for the development of the National Protocol and Service 
Delivery Guidelines on Detection, Prevention and Management of PE/E by PHC Providers, collaboratively 
developed with DGFP, DGHS, OGSB, and other stakeholders, which was approved for use in the invention 
facilities—a demonstrable improvement of baseline conditions (Warren et al 2015). This accomplishment 
likely would not have been realized without Ending Eclampsia’s involvement. Any program for PE/E 
detection, prevention, and management involving PHC providers should have a service delivery protocol in 
place before intervention implementation. Although national policy dissemination to districts and sub-
districts at baseline was sub-optimal (ibid), Ending Eclampsia successfully distributed the service delivery 
guidelines, as a ready reference, to program managers and service providers in the intervention areas.  
The involvement of relevant parties such as DGFP, DGHS, OGSB, Save the Children, Jhpiego, Marie Stopes, 
as well as others helped increase the significance of addressing PE/E through PHC providers, for SDG 
achievement through reduced maternal and neonatal deaths. At endline, most policymakers, program 
managers, and service providers cited improvements in PE/E detection, prevention, and management by 
PHC providers at intervention facilities, and thought expansion of this intervention to other parts of the 
country was necessary for reducing maternal and neonatal morbidity and mortality. This supports WHO’s 
and others’ recommendations, to address PE/E at the PHC level through task sharing (WHO 2015, 2011). 
Training PHC providers in hypertension classification, PE/E, correct BP measurement, albumin urine 
analysis, pregnancy risk assessment, MgSO4 administration, as well as referrals, were key components of 
this intervention, in addition to ensuring facility readiness and commodities. Endline findings indicate 
significant improvements in provider knowledge, skills, and practice (Warren et al 2015). At endline nearly 
all service providers could correctly diagnose SPE/E in hypothetical situations, with far better results than 
those in a recent study from Afghanistan in which only 73 percent of SBAs evinced correct knowledge in 
similar case scenarios (Ansari et al 2019). Although FWVs, SACMOs, and nurses significantly improved their 
knowledge of BP indicating initiation of anti-hypertensive drugs for mild to moderate HDP, only 57 percent 
demonstrated this knowledge at endline, while most physicians demonstrated it at both baseline and 
endline. These findings could be due to the fact that anti-hypertensive drugs were not discussed in training 
because PHC providers are not allowed to prescribe anti-hypertensive drugs to pregnant women. 
Another success of this project is improved knowledge of the loading dose of MgSO4, which increased 
fourteen-fold from baseline: At endline all providers knew the correct loading dose of MgSO4. Although 
knowledge among all providers of the maintenance dose of MgSO4 for SPE/E improved significantly at 
endline (p<0.001), its increase was not as high as expected. The modest increase could be due to the fact 
training emphasized a modified loading dose of MgSO4, mostly for PHC providers and referrals, rather than 
a maintenance dose, which is only supposed to be given at secondary or tertiary facilities. This assumption 
is substantiated by the finding that more physicians likely to work at secondary facilities demonstrated 
knowledge of the maintenance dose at endline, compared to FWVs, SACMOs, and nurses. 
This intervention’s effectiveness was measured according to various indicators, particularly provider 




detection and management, ANC clients’ positive experiences and improved quality of care, improved 
referral mechanisms, and increased service uptake.  
Administration of a loading dose of MgSO4 by all service providers significantly increased (p<0.001): At 
endline, nearly half of FWVs, SACMOs, and nurses, along with more than three fourths of physicians, had 
administered MgSO4. In a similar quasi-experimental study in rural Bangladesh, maternal and neonatal 
deaths significantly decreased among women who had a loading dose administered locally, compared to 
those who did not receive a loading dose and only received a referral (Shamsuddin et al 2005).  
Not all service providers in this study had a chance to administer a loading dose of MgSO4, due to either a 
lack of PE/E patients or operational challenges. The most common challenge at baseline was reluctance 
or refusal of patients and their families for an injection during pregnancy. At endline, the most common 
challenge was providers’ fear of community reactions if patients experienced side effects or died after 
MgSO4 Administration. These are important barriers to consider if there is an expansion of the intervention, 
and moreover, both on- and off site digital mentoring for PE/E detection, prevention, and management 
should be introduced in any expanded program. 
Provider practices for detecting and preventing PE/E—by assessing PE risk, detecting it, and advising of 
impending eclampsia (measured through composite summary score)—was poor at baseline (Warren et al 
2015) but significantly improved at endline. Only two percent of all providers frequently measured patients’ 
BP and proteinuria at baseline, which significantly increased—to 62 percent—at endline, which is another 
aspect of the intervention’s success, and an element that should be promoted within any program that 
plans to address PE/E through PHC providers, including scale up.  
Hodgins et al., in their review articles, conclude that simple interventions during pregnancy, such as PE/E 
detection, have considerable potential impact on important mortality outcomes (Hodgins et al 2018). 
Charanthimath et al. concluded, in a study in India, that task sharing with community-based health workers 
can facilitate early diagnosis of HDP and assist emergency care. Consistent advising by providers on the 
signs and symptoms of PE/E with every ANC client was not followed even at endline—this needs to be 
emphasized in provider trainings. 
Clients reported improved quality of care at endline, consistent with quality of care findings from BDHS 
2017. Ninety-six percent of clients reported BP measurement, consistent with a recent study in Afghanistan 
(Ansari et al 2019). Sixty-five percent of clients at endline reported urine analysis, yet monitoring data 
suggest that 47 percent of all service providers measured albumin in urine in the project areas. Providers 
ascribed low urine testing to uncomfortable environments at clinics and satellite clinics where no toilets 
are available for urination, along with service provider bias in choosing only risky patients and skipping 
testing for negative patients in subsequent visits, often because women themselves want to skip it if a 
previous reports was negative. While testing urine protein for all ANC patients is frequently recommended, 
experts now believe PE is possible without protein in urine (WHO 2011, NICE 2011, Mayo Clinic 2019, Pre-
eclampsia Foundation 2019). Further research is warranted to determine if urine tests are essential, 
particularly for community providers in resource-poor settings. 
The discrepancy of a greater proportion of clients in exit interviews reporting urine analysis than reported 
in the monitoring data may indicate a Hawthorne effect, with service providers modifying their behaviors, 
or even pretending, due to assessment or observation. Monitoring findings also reveal the necessity of 
proper and consistent documentation of all client information, which is lacking in every facility. 
Service delivery statistics show significant improvements in SPE/E treatment as well as BP measurement 
and urine protein checks during ANC visits. If the PHC PE/E model intervention were to be implemented in 




The proportion of pregnant women detected with high BP during ANC visits also increased. If PHC providers 
are trained and actively attempt to detect hypertension during ANC, early HDP diagnoses can be increased.   
While this intervention is a great success, four percent of SPE/E patients at endline were either not given 
MgSO4 before referral, or refused an MgSO4 injection. The barriers preventing fulsome administration of 
MgSO4 should be addressed in any subsequent expansion. In addition, although HDP diagnosis significantly 
increased, the rate is still low, which indicates the need for more programmatic efforts to motivate service 
providers for consistent, correct BP measurement and urine testing for albumin during ANC. 
There were several limitations to this study, starting with unequal sample sizes of ANC observations, exit 
client interviews, and PE/E survivor interviews at baseline and endline. To make the study findings robust, 
different data sources were triangulated, and findings compared. Additionally, service providers’ 
background characteristics at baseline and endline differed, as not all the same providers were interviewed 
at both data collection points, due to transfers or new postings, which may have contributed to differences 
in provider knowledge. Training was provided to every provider included in the intervention, however, to 
equip them with similar knowledge. Finally, a Hawthorne effect may have occurred during observed CPIs, 
whereby service providers modified their behaviors due to their observation.  
Ending Eclampsia employed no rigorous community educational efforts in this Bangladesh program, except 
a PE/E brochure distributed to clients by service providers and field workers. Although a community 
evaluation was not conducted, the facility assessment shows positive impacts on improved client PE/E 
knowledge. The trend of late facility attendance during the antenatal period warrants the urgent attention 
of policymakers and program managers, for strengthened educational efforts within communities and at 
facilities. In two PE/E survivor cases, an infant death at a referral facility was mistakenly linked with an 
injection of a loading dose of MgSO4 by the patients and their families. Attention also needs to be paid to 
patients who abandon the referral process once they receive their MgSO4 injection, which was documented 
in the intervention areas. 
Recommendations 
• The scale up of this PE/E intervention package is widely believed as necessary. It can be accomplished 
through continued training of service providers, as well as ensuring that referral logistics and 
commodities are in place. Three days of training on HDP and PE/E for providers, including a one day 
refresher training after three months following initial training, is recommended. 
• On- and off site digital mentoring for PE/E detection, prevention, and monitoring should be introduced 
in any expanded program. Medical officers-in-charge of PHC providers or district or sub-district obstetric 
and gynecological (Ob/Gyn) consultants should train their PHC providers. Trainers or mentors should 
make sure they provide telephone numbers for PHC providers to contact them for further advice. 
• Every provider should conduct a PE/E risk assessment for all ANC patients that includes advising of the 
signs and symptoms of PE/E and other danger signs and symptoms, along with follow up of identified 
PE/E patients. 
• Rigorous community educational interventions are recommended for early and regular ANC along with 
information on danger signs of pregnancy, including HDPs and use of MgSO4 for SPE/E. 
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Appendix A: Uptake of services  
for 3 months at baseline, 12 month intervention statistics, and PMP indicators 



































Women with pre-eclampsia seen at facility per month  n 8 12 28 48 14 13 29 22 34 26 30 30 41 41 20 19 
Women with severe PE seen at facility per month          n 0 16 4 20 0 29 8 6 13 17 17 6 21 28 16 35 
Women with eclampsia seen at facility per month         n 35 38 69 142 66 28 29 36 57 43 44 41 42 49 70 72 
Women with severe PE/E treated with MgSO4                          n 1 9 23 33 59 56 36 40 66 53 58 45 45 74 80 106 
Women with severe PE/E treated with MgSO4            % 3% 17% 32% 20% 89% 98% 97% 95% 94% 88% 95% 96% 71% 96% 93% 99% 
ANC visits, per month (repeat visits and new)                  n 11,292 12,183 10,279 33,754 11,872 12,218 12,767 13,402 13,705 11,177 15,457 14,662 13,487 15,293 14,361 11,953 
Women whose BP measured in ANC visits                       n  9,173 9,634 10,279 27,404 10,510 10,983 11,133 12,155 12,817 10,363 14,567 14,156 13,035 14,644 14,110 11,609 
% 81% 79% 84% 81% 89% 90% 87% 91% 94% 93% 94% 97% 97% 96% 98% 97% 
Women whose urine checked for albumin at ANC visits n 312 962 669 1943 1,081 3,513 4,856 5,342 5,441 4,794 7,379 7,593 6,825 7,110 7,285 5,537 
% 3% 8% 7% 6% 9% 29% 38% 40% 40% 43% 48% 52% 51% 46% 51% 46% 
Pregnant women detected as high risk patients in ANC 
visits                                                                                     n   702 1026 1068 2796 1820 2485 3056 3213 3334 2753 3522 3836 3851 3995 4044 3126 
%   6% 8% 10% 8% 15% 20% 24% 24% 24% 25% 23% 26% 29% 26% 28% 26% 
Pregnant women detected with high BP during ANC 
visits                                                                                     n   8 90 69 167 75 64 128 152 202 147 237 169 249 182 147 157 
% 0.001 0.007 0.007 0.005 0.006 0.005 0.010 0.011 0.015 0.013 0.015 0.012 0.018 0.012 0.010 0.013 
Mid-level providers trained on PE/E management  
in intervention area                                                             n   399 399 - - - - - - - - - - - - 
Mid-level providers who can correctly identify and 
detect PE                                                                    % - - - - - - - - - - - - - - - - 
Mid-level providers who can correctly identify and 
detect eclampsia                                                       % - - - - - - - - - - - - - - - - 
Mid-level providers trained (49) to competence 
in appropriate anti-hypertensive use                       %                                                                    - - - - - - - - 100%        
Trained providers prescribing anti-hypertensive drugs  
to control BP among PE/E patients at intervention site  n  - - - 
(49+44 
trained) - - - - 3 4 5 5 6 4 3 5 
Pregnant women who attended ANC aware of 2+ PE/E 





Appendix B Uptake of services  
for second year intervention statistics, totals, and PMP indicators 
























(in 136 facilities)  
Jan ’17-Dec ’18  
(24 months) 
Women with pre-eclampsia seen at facility per month                    n 28 29 30 29 21 11 31 29 40 42 30 25 664 
Women with severe PE seen at facility per month                           n 31 46 11 26 14 9 16 14 24 21 21 16 445 
Women with eclampsia seen at facility per month                          n 84 102 91 78 74 68 54 58 65 120 131 52 1554 
Women with severe PE/E treated with MgSO4                                                      n 111 140 102 100 86 77 68 71 86 133 150 68 1910 
Women with severe PE/E treated with MgSO4                                        % 97% 95% 100% 96% 98% 100% 97% 99% 97% 94% 99% 100% 96% 
ANC visits, per month (repeat visits and new)                                   n 13,641 13,630 14,014 13,729 13,325 12,470 15,995 14,518 16,216 16,272 15,046 15,095 334,305 
Women whose BP measured in ANC visits                                        n 13,169 13,222 13,664 13,391 13,054 12,267 15,788 14,218 16,048 16,083 14,650 14,743 320,379 
% 97% 97% 98% 98% 98% 98% 99% 98% 99% 99% 97% 98% 96% 
Women whose urine checked for albumin at ANC visits                  n 6,778 7,271 7,070 7,913 7,027 6,022 8,077 7,725 7,769 7,958 7,997 8,164 156,527 
% 50% 53% 50% 58% 53% 48% 50% 53% 48% 49% 53% 54% 47% 
Pregnant women detected as high risk patients in ANC visits        n 2,910 3,252 3,487 3,079 2,725 2,732 3,508 3,106 3,557 3,386 3,308 3,418 77,503 
%                                                         21% 24% 25% 22% 20% 22% 22% 21% 22% 21% 22% 23% 23% 
Pregnant women detected with high BP during ANC visits              n 213 197 184 189 139 117 167 180 179 143 147 194 3,958 
% 0.016 0.014 0.013 0.014 0.010 0.009 0.010 0.012 0.011 0.009 0.010 0.013 0.012 
Mid-level providers trained on PE/E management in intervention 
area (refresher)*                                                                                   n 118* 99* - - - - - - - - -  217* 
Mid-level providers who can correctly identify and detect PE         % - - - - - - 93% - - -   
Mid-level providers who can correctly identify and detect E            % - - - - - - 94% - - -   
Mid-level providers trained (44) to competence in appropriate 
anti-hypertensive use (refresher)*                                             % 90%*       - - - -   
Trained service providers prescribing anti-hypertensive drugs to 
control BP among PE/E patients at intervention site                       n 4 8 7 5 4 3 6 - - - -   
Pregnant women who attended ANC aware of 2+ PE/E 
signs/symptoms                                                                                  % - - - - - - 34% - - -   
 
